Abstract
With the discovery of RNA interference technology, small-interfering RNA (siRNA) has emerged as new powerful tool for gene therapy because of its high targeting specificity and selectivity. However, one of the limitations to successful gene therapy is the inability to monitor delivery of genes and therapeutic responses at the targeted site. Hence, a combinatorial approach of gene therapy with molecular imaging has been crucial in optimizing gene therapy. Recent advances in nanotechnology have made tremendous efforts to develop multifunctional nanoparticles that contain imaging and therapeutic agents together for image-guided therapy. The nanoparticles serve as contrast agents in imaging for disease detection with simultaneous delivery of therapeutics to cure the diseases. The therapy also helps to monitor the drug accumulation and assimilation in the body, thereby facilitating the evaluation of treatment effects. Here, we present an overview of polymer and lipid-based carriers for siRNA delivery, along with imaging agents as imageguided therapy, in the treatment of breast, lung, liver, ovarian, cervical, and prostate cancers.
Keywords: RNA interference, gene therapy, nanotechnology, imaging agents, cancer theragnosis.
Current Pharmaceutical Design
Title:Image-Guided Nanoparticle-Based siRNA Delivery for Cancer Therapy
Volume: 21 Issue: 31
Author(s): Yong-Dong Kim, Tae-Eun Park, Bijay Singh, Sushila Maharjan, Kye-Soo Cho, Kyoung Pyo Park, Yun-Jaie Choi, Rohidas B. Arote and Chong-Su Cho
Affiliation:
Keywords: RNA interference, gene therapy, nanotechnology, imaging agents, cancer theragnosis.
Abstract: With the discovery of RNA interference technology, small-interfering RNA (siRNA) has emerged as new powerful tool for gene therapy because of its high targeting specificity and selectivity. However, one of the limitations to successful gene therapy is the inability to monitor delivery of genes and therapeutic responses at the targeted site. Hence, a combinatorial approach of gene therapy with molecular imaging has been crucial in optimizing gene therapy. Recent advances in nanotechnology have made tremendous efforts to develop multifunctional nanoparticles that contain imaging and therapeutic agents together for image-guided therapy. The nanoparticles serve as contrast agents in imaging for disease detection with simultaneous delivery of therapeutics to cure the diseases. The therapy also helps to monitor the drug accumulation and assimilation in the body, thereby facilitating the evaluation of treatment effects. Here, we present an overview of polymer and lipid-based carriers for siRNA delivery, along with imaging agents as imageguided therapy, in the treatment of breast, lung, liver, ovarian, cervical, and prostate cancers.
Export Options
About this article
Cite this article as:
Kim Yong-Dong, Park Tae-Eun, Singh Bijay, Maharjan Sushila, Cho Kye-Soo, Park Pyo Kyoung, Choi Yun-Jaie, Arote B. Rohidas and Cho Chong-Su, Image-Guided Nanoparticle-Based siRNA Delivery for Cancer Therapy, Current Pharmaceutical Design 2015; 21 (31) . https://dx.doi.org/10.2174/138161282131151013192327
DOI https://dx.doi.org/10.2174/138161282131151013192327 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Proteomics on Fixed Tissue Specimens – A Review
Current Proteomics The Contractile Properties of Airway Smooth Muscle: How their Defects can be Linked to Asthmatic Airway Hyperresponsiveness?
Current Respiratory Medicine Reviews Anti-Cancer/Anti-Tumor
Current Bioactive Compounds Molecular Targets from VHL Studies into the Oxygen-Sensing Pathway
Current Cancer Drug Targets The Important Roles of miR-205 in Normal Physiology, Cancers and as a Potential Therapeutic Target
Current Cancer Drug Targets Neurorestorative Role of Stem Cells in Alzheimer’s Disease: Astrocyte Involvement
Current Alzheimer Research Gemcitabine Resistance is Associated with Epithelial-Mesenchymal Transition and Induction of HIF-1α in Pancreatic Cancer Cells
Current Cancer Drug Targets Procyanidin B2 3,3″-di-O-gallate Inhibits Endothelial Cells Growth and Motility by Targeting VEGFR2 and Integrin Signaling Pathways
Current Cancer Drug Targets Therapeutic Nucleic Acids
Recent Patents on Regenerative Medicine Addressing Unmet Medical Needs in Type 2 Diabetes: A Narrative Review of Drugs under Development
Current Diabetes Reviews Polyploidy: The Link Between Senescence and Cancer
Current Pharmaceutical Design Patent Selections
Recent Patents on DNA & Gene Sequences Therapeutic Polycomb Targeting in Human Cancer
Recent Patents on Regenerative Medicine Ellagic Acid: Cytodifferentiating and Antiproliferative Effects In Human Prostatic Cancer Cell Lines
Current Pharmaceutical Design Lipid Nanoparticles and their Application in Nanomedicine
Current Pharmaceutical Biotechnology Current Perspectives on Anti-Aging Interventions
Letters in Drug Design & Discovery Thermosensitive Liposomes in Cancer Therapy
Recent Patents on Biomedical Engineering (Discontinued) Mechanism of Action of Antitumor Drugs that Interact with Microtubules and Tubulin
Current Medicinal Chemistry - Anti-Cancer Agents Biomedical Applications of Zinc Oxide Nanomaterials
Current Molecular Medicine Indoleamine 2,3-Dioxygenase in Immune Suppression and Cancer
Current Cancer Drug Targets